{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jeannot E"],"funding":["Fondation ARC pour la Recherche sur le Cancer","European Commission"],"pagination":["5869-5877"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401545"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(21)"],"pubmed_abstract":["<h4>Purpose</h4>Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period.<h4>Experimental design</h4>We analyzed serum samples from 94 HPV16- or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV <i>E7</i> gene as a marker for residual disease compared to HPV integration site and <i>PIK3CA</i> mutations. Finally, the prognostic impact of circulating HPV <i>E7</i> gene was assessed with its prediction value of relapse.<h4>Results</h4>HPV <i>E7</i> gene was the most sensitive tumor marker, superior to both HPV integration sites and <i>PIK3CA</i> mutations in serum. Circulating HPV DNA (HPV ctDNA) was detected in 63% (59/94) of patients, before treatment. HPV ctDNA detection in serum sample was associated with high FIGO stage (<i>P</i> = 0.02) and para-aortic lymph node involvement (<i>P</i> = 0.01). The level of HPV ctDNA was positively correlated with HPV copy number in the tumor (<i>R</i> = 0.39, <i>P</i> < 0.001). Complete clearance of HPV ctDNA by the end of treatment was significantly associated with a longer PFS (<i>P</i> < 0.0001). Patients with persistent HPV ctDNA in serum relapsed with a median time of 10 months (range, 2-15) from HPV ctDNA detection.<h4>Conclusions</h4>HPV ctDNA detection is a useful marker to predict relapse in cervical cancer.<i>See related commentary by Wentzensen and Clarke, p. 5733</i>."],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer."],"pmcid":["PMC9401545"],"funding_grant_id":["304810"],"pubmed_authors":["de la Rochefordiere A","Dureau S","Popovic M","Bonneau C","Raizonville L","Larbi Cherif L","Fourchotte V","Bieche I","Le Tourneau C","Berns EMJJ","Dupain C","Latouche A","Bataillon G","Beaufort C","Jeannot E","Tran-Perennou C","Kamal M","Rouzier R","Lecuru F","Lecerf C","Calmejane MA","Ruigrok-Ritstier K","Bello Roufai D","Legrier ME","Scholl S","von der Leyen H","Jordanova ES"],"additional_accession":[]},"is_claimable":false,"name":"Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.","description":"<h4>Purpose</h4>Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period.<h4>Experimental design</h4>We analyzed serum samples from 94 HPV16- or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV <i>E7</i> gene as a marker for residual disease compared to HPV integration site and <i>PIK3CA</i> mutations. Finally, the prognostic impact of circulating HPV <i>E7</i> gene was assessed with its prediction value of relapse.<h4>Results</h4>HPV <i>E7</i> gene was the most sensitive tumor marker, superior to both HPV integration sites and <i>PIK3CA</i> mutations in serum. Circulating HPV DNA (HPV ctDNA) was detected in 63% (59/94) of patients, before treatment. HPV ctDNA detection in serum sample was associated with high FIGO stage (<i>P</i> = 0.02) and para-aortic lymph node involvement (<i>P</i> = 0.01). The level of HPV ctDNA was positively correlated with HPV copy number in the tumor (<i>R</i> = 0.39, <i>P</i> < 0.001). Complete clearance of HPV ctDNA by the end of treatment was significantly associated with a longer PFS (<i>P</i> < 0.0001). Patients with persistent HPV ctDNA in serum relapsed with a median time of 10 months (range, 2-15) from HPV ctDNA detection.<h4>Conclusions</h4>HPV ctDNA detection is a useful marker to predict relapse in cervical cancer.<i>See related commentary by Wentzensen and Clarke, p. 5733</i>.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-06-24T03:19:02.766Z","creation":"2025-04-04T13:08:56.247Z"},"accession":"S-EPMC9401545","cross_references":{"pubmed":["34210686"],"doi":["10.1158/1078-0432.CCR-21-0625"]}}